Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Total Non-Current Liabilities (2017 - 2025)

Pharma-Bio Serv filings provide 9 years of Total Non-Current Liabilities readings, the most recent being $1.7 million for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities changed N/A to $1.7 million in Q3 2025 year-over-year; TTM through Jul 2025 was $1.7 million, a N/A change, with the full-year FY2024 number at $1.9 million, changed N/A from a year prior.
  • Total Non-Current Liabilities hit $1.7 million in Q3 2025 for Pharma-Bio Serv, down from $1.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $8.9 million in Q1 2021 to a low of $1.7 million in Q3 2025.
  • Median Total Non-Current Liabilities over the past 5 years was $4.2 million (2022), compared with a mean of $3.9 million.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 77.42% in 2021 and later plummeted 50.81% in 2022.
  • Pharma-Bio Serv's Total Non-Current Liabilities stood at $5.0 million in 2021, then plummeted by 50.81% to $2.5 million in 2022, then rose by 9.34% to $2.7 million in 2023, then dropped by 28.6% to $1.9 million in 2024, then fell by 13.42% to $1.7 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $1.7 million (Q3 2025), $1.8 million (Q2 2025), and $1.9 million (Q4 2024) per Business Quant data.